Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues.

Gillis, N K; Innocenti, F

Gillis, N K; Innocenti, F.

Affiliation

Gillis NK; Center for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Innocenti F; 1] Center for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA [2] Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

Clin Pharmacol Ther ; 96(6): 655-7, 2014 Dec.

Article in En | MEDLINE | ID: mdl-25399714

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmacogenetics / Genetic Testing Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2014 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google